E Fund Management Co. Ltd. Cuts Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

E Fund Management Co. Ltd. trimmed its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 11.5% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,675 shares of the company’s stock after selling 2,686 shares during the period. E Fund Management Co. Ltd.’s holdings in Sana Biotechnology were worth $113,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Victory Capital Management Inc. purchased a new position in Sana Biotechnology during the 4th quarter valued at about $54,000. Hartline Investment Corp purchased a new position in shares of Sana Biotechnology in the first quarter valued at approximately $136,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Sana Biotechnology by 20.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company’s stock valued at $163,000 after purchasing an additional 5,090 shares in the last quarter. Arizona State Retirement System increased its stake in Sana Biotechnology by 36.7% during the 2nd quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock worth $202,000 after buying an additional 9,940 shares during the period. Finally, ProShare Advisors LLC lifted its holdings in Sana Biotechnology by 14.8% during the 1st quarter. ProShare Advisors LLC now owns 32,690 shares of the company’s stock worth $327,000 after buying an additional 4,210 shares in the last quarter. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

Sana Biotechnology Price Performance

NASDAQ:SANA opened at $4.62 on Friday. Sana Biotechnology, Inc. has a 12 month low of $2.74 and a 12 month high of $12.00. The business’s fifty day moving average price is $5.44 and its 200 day moving average price is $7.12.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). As a group, equities research analysts predict that Sana Biotechnology, Inc. will post -1.13 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on SANA shares. Citigroup upped their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Rodman & Renshaw started coverage on Sana Biotechnology in a research note on Wednesday, June 26th. They issued a “buy” rating and a $16.00 price objective for the company. Finally, HC Wainwright cut their target price on shares of Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, August 9th.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.